Skip to main content

Research News

academics

 

Clinical research courses

  • NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain

    The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.

  • New drug tested to reduce side effect of ‘half-matched’ stem cell transplants
    Stem cell transplantation, using devices like the one shown here, is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a clinical trial conducted by researchers at WashU Medicine showed adding the investigational drug itacitinib to standard care for half-matched stem cell transplantation may reduce rates of the disease, in which the donor’s stem cells attack the patient’s healthy tissues.
  • Wearable devices can help predict five year risk of falls for people with Parkinson’s Disease
    Falls are a common problem for people living with Parkinson’s. A recent review estimated that some 60% of all people living with PD have experienced at least one fall. These can lead to injury and hospitalisation, as well as reduced mobility, quality of life, and life expectancy.
  • Network-based analyses uncover how neuroinflammation-causing microglia in Alzheimer’s disease form

    Cleveland Clinic Genome Center researchers have unraveled how immune cells called microglia can transform and drive harmful processes like neuroinflammation in Alzheimer’s disease. The study, published in Alzheimer’s & Dementia: The Journal of The Alzheimer’s Association, also integrates drug databases with real-world patient data to identify FDA-approved drugs that may be repurposed to target disease-associated microglia in Alzheimer’s disease without affecting the healthy type. 

  • Natural Biopesticide Against Malaria Mosquitoes Successful in Early Field Tests

    An experimental bacteria-derived biopesticide is highly effective in killing malaria-carrying mosquitoes, including those that have developed resistance to chemical pesticides, according to initial field tests led by researchers at the Johns Hopkins Bloomberg School of Public Health.

  • New method offers insights into Alzheimer’s mechanisms and potential drug targets

    Researchers at Columbia University Mailman School of Public Health have developed a novel computational pipeline designed to identify protein biomarkers associated with complex diseases, including Alzheimer’s disease (AD). This innovative tool analyzes biomarkers that can induce 3D structural changes in proteins, providing critical insights into disease mechanisms and highlighting potential targets for therapeutic intervention.

  • Bacteria modify ribosomes to dodge antibiotics
    Bacteria modify their ribosomes when exposed to widely used antibiotics, according to research published in Nature Communications. The subtle changes might be enough to alter the binding site of drug targets and constitute a possible new mechanism of antibiotic resistance.
  • Some cancer treatments boost risk of heart disease, new mechanism found
    A cancer therapy that prompts the bodys immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the largest blood vessels of heart
  • Different menopausal hormone treatments pose different risks

    Researchers have analysed the effects of seven different hormone treatments for menopausal symptoms, and the risk of blood clots, stroke and heart attack. The risks differ depending on the active substance and how the medicine is taken. The study involves around one million women aged 50-58 and is the largest and most comprehensive study of currently prescribed hormonal substances in the world. 

  • Monash study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system

    Effective immunity hinges on the ability to sense infection and cellular transformation. In humans, there is a specialised molecule on the surface of cells termed MR1. MR1 allows sensing of certain small molecule metabolites derived from cellular and microbial sources; however, the breadth of metabolite sensing is unclear.

Subscribe to Research News